The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents
Open accessAbstract
Chloroquine (CQ) and hydroxychloroquine (HCQ) are well-known 4-aminoquinoline antimalarial agents. Scientific evidence also supports the use of CQ and HCQ in the treatment of cancer. Overall, preclinical studies support CQ and HCQ use in anti-cancer therapy, especially in combination with conventional anti-cancer treatments since they are able to sensitise tumour cells to a variety of drugs, potentiating the therapeutic activity. Thus far, clinical results are mostly in favour of the repurposing of CQ. However, over 30 clinical studies are still evaluating the activity of both CQ and HCQ in different cancer types and in combination with various standard treatments. Interestingly, CQ and HCQ exert effects both on cancer cells and on the tumour microenvironment. In addition to inhibition of the autophagic flux, which is the most studied anti-cancer effect of CQ and HCQ, these drugs affect the Toll-like receptor 9, p53 and CXCR4-CXCL12 pathway in cancer cells. In the tumour stroma, CQ was shown to affect the tumour vasculature, cancer-associated fibroblasts and the immune system. The evidence reviewed in this paper indicates that both CQ and HCQ deserve further clinical investigations in several cancer types. Special attention about the drug (CQ versus HCQ), the dose and the schedule of administration should be taken in the design of new trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal
Ndiaye, M., Lespez, L., Tribolo, C., Rassé, M., Hadjas, I., Davidoux, S., Huysecom, É., & Douze, K. (2024) · Monash University Research Portal (Monash University) · doi:10.3929/ethz-b-000667478 · Cited by 23,868
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
De Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,136
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Autophagy: cellular and molecular mechanisms
Glick, D., Barth, S., & Macleod, K. F. (2010) · The Journal of Pathology · doi:10.1002/path.2697 · Cited by 3,802
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
An Overview of Autophagy: Morphology, Mechanism, and Regulation
Parzych, K. R., & Klionsky, D. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5371 · Cited by 2,521
Cited by
Lysosomal membrane permeabilization and cell death
Wang, F., Gómez‐Sintes, R., & Boya, P. (2018) · Traffic · doi:10.1111/tra.12613 · Cited by 776
Complex interplay between autophagy and oxidative stress in the development of pulmonary disease
Ornatowski, W., Lu, Q., Yegambaram, M., Garcia, A. E., Zemskov, E. A., Maltepe, E., Fineman, J. R., Wang, T., & Black, S. M. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101679 · Cited by 467
Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications
Nazio, F., Bordi, M., Cianfanelli, V., Locatelli, F., & Cecconi, F. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-019-0292-y · Cited by 388
Patergnani, S., Danese, A., Bouhamida, E., Aguiari, G., Previati, M., Pinton, P., & Giorgi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218323 · Cited by 350
Plantone, D., & Koudriavtseva, T. (2018) · Clinical Drug Investigation · doi:10.1007/s40261-018-0656-y · Cited by 305
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Drug repurposing to overcome resistance to various therapies for colorectal cancer
Fong, W., & To, K. K. W. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03134-0 · Cited by 81
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
“Their antitumor effects are mainly attributable to the inhibition of autophagy, which in turn prevents degradation of metabolic stress products and thus promotes cell apoptosis [134,136].”
BackgroundRabben, H.-L., Andersen, G. T., Ianevski, A., Olsen, M. K., Kainov, D., Grønbech, J. E., Wang, T. C., Chen, D., & Zhao, C.-M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.625991 · Cited by 24
“Of note is that both the preclinical and clinical safety data are available (Verbaanderd et al., 2017; Antoszczak et al., 2020).”
BackgroundMarastoni, S., Madariaga, A., Pesic, A., Nair, S. N., Li, Z. J., Shalev, Z., Ketela, T., Colombo, I., Mandilaras, V., Cabanero, M., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0037 · Cited by 19
Antiangiogenesis Effect of Albendazole on the Cornea
Cho, Y. K., Shin, E. Y., Uehara, H., & Ambati, B. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0103 · Cited by 7
Metadata
- Authors
- Verbaanderd, C., Maes, H., Schaaf, M. B., Sukhatme, V. P., Pantziarka, P., Sukhatme, V., Agostinis, P., & Bouche, G.
- Venue
- ecancermedicalscience
- Publisher
- Ecancer Global Foundation
- Published
- 2017-11-23
- Volume
- 11
- Pages
- 781-781
- ISSN
- 1754-6605 (ISSN-L)
- OpenAlex
- W2768197901
- Cited by
- 275
- References
- 172
- FWCI
- 17.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.